Clinical Trial

Development of a Non-invasive Method for Quantifying Cerebral Glucose Metabolism for Studying the Effect of Glucagon in Humans

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 17, 2024 (before its estimated December 17, 2024 completion). Its status may not reflect the trial's current state.
Summary
The aim of the study is to develop a non-invasive method for quantifying cerebral glucose metabolism by PET scans in humans. This method will be used in subsequent studies, where the effect of the pancreatic hormone glucagon on cerebral glucose metabolism will be studied. The golden standard for quantifying cerebral glucose metabolism by PET scans is based on arterial blood sampling, which complicates research setup. This study will investigate if image derived measurements instead of arterial blood samples can be used to quantify cerebral glucose metabolism. We will compare the calculations of cerebral glucose metabolism based on arterial blood samples and image derived measurements and hopefully these will correlate. Healthy participants will be included, and each participant will participate in one study day, which includes intravenous administration of radioactively labelled glucose (18-FDG), arterial blood sampling and PET scans.
Trial Details
NCT Number NCT06647368
Lead Sponsor Nicolai Jacob Wewer Albrechtsen
Collaborators: University Hospital Bispebjerg and Frederiksberg
Conditions Cerebral Glucose Metabolism
Enrollment 6 participants
Start Date 2024-10-22
Primary Completion 2024-12-17 (estimated)
Study Completion 2024-12-17 (estimated)
Updated on ClinicalTrials.gov 2024-10-17